ClinicalTrials.gg
CompletedNCT03077412Divergence2Updated Apr 8, 2022Results posted

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Fistulizing Crohn's Disease, sponsored by Gilead Sciences. Completed at 27 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
273rd of 528
57 · median 60
Started
2017
with 36 others
Phase 2
141 of 660
23 open now
Registered
337th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 273rd largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 141 in phase 2, and was the 337th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate Long-Term Extension (LTE) study (GS-US-419-3896; NCT02914600) if they meet eligibility requirements.

03

Conditions studied

  • Fistulizing Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of screening visit
  • Diagnosis of Crohn's disease (CD) with a minimum duration of CD of at least 3 months
  • Has draining perianal fistulae as a complication of CD, confirmed by magnetic resonance imaging (MRI) at screening
  • Previously demonstrated an inadequate clinical response, loss of response to, or intolerance of at least 1 of the following agents (depending on current country treatment recommendations/guidelines):

    • Antibiotics AND/OR
    • Immunomodulators AND/OR
    • Tumor necrosis factor α (TNFα) Antagonist
  • Is willing and able to undergo MRI per protocol requirements
  • Is willing and able to undergo flexible sigmoidoscopy per protocol requirements

Key Exclusion Criteria:

  • Presence of current rectovaginal anovaginal or enterovesicular fistulae
  • Presence of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon
  • History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study
  • Use of any prohibited concomitant medications as described in the study protocol
  • Active tuberculosis (TB) or history of latent TB that has not been treated

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Experimental
    Filgotinib 100 mg

    Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Experimental
    Placebo

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks

    Drug: Placebo to match filgotinib

Interventions

  • Tablet(s) administered orally once daily

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo to match filgotinib

    Tablet(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Combined Fistula Response at Week 24

    Combined fistula response at Week 24 was defined as reduction of greater than or equal to (≥) 1 from baseline in the number of draining external perianal fistula openings that were present at baseline, and absence of fluid collections \> 1 centimeter (cm) on magnetic resonance imaging (MRI) pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieved Combined Fistula Remission at Week 24

    Combined fistula remission at Week 24 was defined as perianal fistula closure of all external openings that were draining at baseline, and absence of fluid collections \> 1 cm on MRI of pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.

    Time frame: Week 24

  2. Time to Clinical Fistula Response up to Week 24

    Time to clinical fistula response was defined as the time interval in days from date of first dosing of study drug to the first observation (during scheduled or unscheduled clinical visits) when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieves perianal fistula closure, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula response were to have their clinical fistula response time censored at the last time that lack of clinical fistula response was documented.

    Time frame: Time from treatment start to first visit when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieved perianal fistula closure up to Week 24

  3. Time to Clinical Fistula Remission up to Week 24

    Time to clinical fistula remission was defined as the time interval in days from date of first dosing of study drug to the first observation (during schedule or unscheduled clinical visits) of perianal fistula closure of all external openings that were draining at baseline, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula remission were have their clinical fistula remission time censored at the last time that lack of clinical fistula remission was documented.

    Time frame: Time from treatment start to first visit when perianal fistula closure takes place of all external openings that were draining at baseline up to Week 24

  4. Percentage of Participants Who Achieved Proctitis Remission at Week 24

    The simple endoscopic score for Crohn's disease (SES-CD) score evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and presence of narrowings). The total SES-CD is calculated as the sum of the 4 variables for the required bowel segment. Values are given to each variable and for every examined bowel segment. The SES-CD size of ulcer subscore ranges from 0 (none) to 3 (very large) and for ulcerated surface subscore ranges from 0 (none) to 3 (\>30 % of affected area). Higher value of the subscore indicates disease worsening. Proctitis remission at Week 24 was defined as a proctitis SES-CD score (sum of ulcer size and ulcerated surface SES-CD endoscopy subscores for the rectum and anal canal) of 0 assessed by centrally read flexible sigmoidoscopy at Week 24, in participants that had moderately to severely active proctitis at baseline. Moderately to Severely Active Proctitis defined as proctitis SES-CD Score \> 2.

    Time frame: Week 24

07

Results

Posted Apr 8, 2022

Participant flow

Participants were enrolled at study sites in Europe and the United States. The first participant was screened on 06 April 2017. The last study visit occurred on 17 February 2021.

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mgPlacebo
Started172515
Completed14126
Not completed3139
Withdrew: Non-responder [crohn's disease activity index (cdai) and perianal cdai non-response] at week 10153
Withdrew: Protocol-specified disease worsening133
Withdrew: Adverse event122
Withdrew: Investigator's discretion011
Withdrew: Withdrew consent020

Outcome measures

PrimaryPercentage of Participants Who Achieved Combined Fistula Response at Week 24

Combined fistula response at Week 24 was defined as reduction of greater than or equal to (≥) 1 from baseline in the number of draining external perianal fistula openings that were present at baseline, and absence of fluid collections \> 1 centimeter (cm) on magnetic resonance imaging (MRI) pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Combined Fistula Response at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Combined Fistula Response at Week 2447.1 (26.0 to 68.9)29.2 (14.6 to 47.9)25.0 (7.2 to 52.7)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in percentages: 22.1 · 90% CI -9.9 to 50.0The 90% exact confidence interval (CI) was calculated based on binomial distribution (Clopper-Pearson method).
  • Filgotinib 100 mg vs Placebo · Risk difference in percentages: 4.2 · 90% CI -26.5 to 34.3The 90% exact CI was calculated based on binomial distribution (Clopper-Pearson method).
SecondaryPercentage of Participants Who Achieved Combined Fistula Remission at Week 24

Combined fistula remission at Week 24 was defined as perianal fistula closure of all external openings that were draining at baseline, and absence of fluid collections \> 1 cm on MRI of pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Combined Fistula Remission at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Combined Fistula Remission at Week 2447.1 (26.0 to 68.9)25.0 (11.5 to 43.5)16.7 (3.0 to 43.8)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in percentages: 30.4 · 90% CI -1.3 to 57.3The 90% exact CI was calculated based on binomial distribution (Clopper-Pearson method).
  • Filgotinib 100 mg vs Placebo · Risk difference in percentages: 8.3 · 90% CI -22.5 to 38.1The 90% exact CI was calculated based on binomial distribution (Clopper-Pearson method).
SecondaryTime to Clinical Fistula Response up to Week 24

Time to clinical fistula response was defined as the time interval in days from date of first dosing of study drug to the first observation (during scheduled or unscheduled clinical visits) when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieves perianal fistula closure, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula response were to have their clinical fistula response time censored at the last time that lack of clinical fistula response was documented.

Time frame:
Time from treatment start to first visit when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieved perianal fistula closure up to Week 24
Reported as:
Median · days
Time to Clinical Fistula Response up to Week 24
daysFilgotinib 200 mgFilgotinib 100 mgPlacebo
Time to Clinical Fistula Response up to Week 2415 (15 to 28)16 (15 to 71)35.5 (15 to 71)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Hazard ratio (hr): 1.26 · 90% CI 0.64 to 2.49Hazard ratio was derived from Cox Proportional-Hazards model.
  • Filgotinib 100 mg vs Placebo · Hazard ratio (hr): 0.90 · 90% CI 0.47 to 1.75Hazard ratio was derived from Cox Proportional-Hazards model.
SecondaryTime to Clinical Fistula Remission up to Week 24

Time to clinical fistula remission was defined as the time interval in days from date of first dosing of study drug to the first observation (during schedule or unscheduled clinical visits) of perianal fistula closure of all external openings that were draining at baseline, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula remission were have their clinical fistula remission time censored at the last time that lack of clinical fistula remission was documented.

Time frame:
Time from treatment start to first visit when perianal fistula closure takes place of all external openings that were draining at baseline up to Week 24
Reported as:
Median · days
Time to Clinical Fistula Remission up to Week 24
daysFilgotinib 200 mgFilgotinib 100 mgPlacebo
Time to Clinical Fistula Remission up to Week 2415 (15 to 70)29 (16 to 74)71 (26 to NA)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Hazard ratio (hr): 1.87 · 90% CI 0.87 to 4.01Hazard ratio was derived from Cox Proportional-Hazards model.
  • Filgotinib 100 mg vs Placebo · Hazard ratio (hr): 1.37 · 90% CI 0.65 to 2.92Hazard ratio was derived from Cox Proportional-Hazards model.
SecondaryPercentage of Participants Who Achieved Proctitis Remission at Week 24

The simple endoscopic score for Crohn's disease (SES-CD) score evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and presence of narrowings). The total SES-CD is calculated as the sum of the 4 variables for the required bowel segment. Values are given to each variable and for every examined bowel segment. The SES-CD size of ulcer subscore ranges from 0 (none) to 3 (very large) and for ulcerated surface subscore ranges from 0 (none) to 3 (\>30 % of affected area). Higher value of the subscore indicates disease worsening. Proctitis remission at Week 24 was defined as a proctitis SES-CD score (sum of ulcer size and ulcerated surface SES-CD endoscopy subscores for the rectum and anal canal) of 0 assessed by centrally read flexible sigmoidoscopy at Week 24, in participants that had moderately to severely active proctitis at baseline. Moderately to Severely Active Proctitis defined as proctitis SES-CD Score \> 2.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Proctitis Remission at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Proctitis Remission at Week 2410.0 (0.5 to 39.4)15.4 (2.8 to 41.0)28.6 (5.3 to 65.9)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in percentages: -18.6 · 90% CI -55.6 to 21.3The 90% exact CI was calculated based on binomial distribution (Clopper-Pearson method).
  • Filgotinib 100 mg vs Placebo · Risk difference in percentages: -13.2 · 90% CI -51.0 to 24.1The 90% exact CI was calculated based on binomial distribution (Clopper-Pearson method).

Adverse events

Collected over All-Cause Mortality: First dose date up to 24 weeks plus 30 days; Adverse Events: First dose date up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg0/17 (0%)5/17 (29.4%)13/17 (76.5%)
Filgotinib 100 mg0/25 (0%)2/25 (8%)14/25 (56%)
Placebo0/15 (0%)1/15 (6.7%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
Crohn's diseaseGastrointestinal disorders1/172/250/15
Vulval abscessInfections and infestations0/170/251/15
Intestinal obstructionGastrointestinal disorders1/170/250/15
Large intestinal stenosisGastrointestinal disorders1/170/250/15
BronchitisInfections and infestations1/170/250/15
Suspected COVID-19Infections and infestations1/170/250/15
Most frequent other events
Showing 10 of 67
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
FatigueGeneral disorders3/173/250/15
Anal abscessInfections and infestations3/170/251/15
InfluenzaInfections and infestations3/171/252/15
ArthralgiaMusculoskeletal and connective tissue disorders3/172/250/15
Anal fistulaGastrointestinal disorders2/172/252/15
NasopharyngitisInfections and infestations2/172/252/15
RashSkin and subcutaneous tissue disorders1/171/252/15
Crohn's diseaseGastrointestinal disorders2/172/251/15
NauseaGastrointestinal disorders2/172/251/15
Oral herpesInfections and infestations2/170/251/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Mean39 ± 11.241 ± 14.039 ± 11.840 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Female910423
Male8151134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Race — American Indian or Alaska Native0000
Race — Asian0202
Race — Black or African American1214
Race — Native Hawaiian or Pacific Islander0000
Race — White15191448
Race — Other0000
Race — Not Permitted1203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Ethnicity — Not Hispanic or Latino17231555
Ethnicity — Hispanic or Latino0101
Ethnicity — Not Permitted0101
Region of Enrollment
Region of Enrollment(participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Canada1315
Austria4228
Belgium1113
Hungary1113
United States415827
United Kingdom1001
Italy0011
France2305
Germany3014
08

Study locations

27 sites
  • University of Miami Crohn's and Colitis Center
    Miami, Florida 33136, United States
  • Center for Interventional Endoscopy - Florida Hospital
    Orlando, Florida 32804, United States
  • University of South Florida South Tampa Campus
    Tampa, Florida 33606, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Louisville Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • John Hopkins Gastroenterology and Hepatology Services at the Green Spring Station Clinic
    Baltimore, Maryland 21224, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center - IBD Clinic
    Nashville, Tennessee 37212-2702, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
  • Medical University of Vienna, Department of Internal Medicine III, Division Gastroenterology and Hepatology
    Vienna, 1090, Austria
  • Universitaire Ziekenhuizen Leuven
    Leuven, B-3000, Belgium
  • Mount Sinai Hospital
    Toronto, M5T 3L9, Canada
  • Toronto Digestive Disease Associates Inc.
    Toronto, M9V 4B8, Canada
  • CHU Grenoble Alpes - Hopital Michallon (main office)
    La Tronche, 38700, France
  • CHU de Rennes - Hôpital Pontchaillou (main office)
    RENNES Cedex 9, 85809, France
  • CHU Nancy - Hopital de Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • Universitatsklinkum Jena
    Jena, 07747, Germany
  • Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórháza
    Bekescsaba, Bekes 5600, Hungary
  • Bugát Pál Kórház, Gasztroenterológiai osztály
    Gyöngyös, Heves 3200, Hungary
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Royal Devon and Exeter Hospital, Department of Gastroenterology
    Exeter, EX2 5DW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jan 2021, 45 months.

Results were first posted in Apr 2022, 1 year 2 months after primary completion. A results delay was requested in Oct 2021.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 13, 2017
StartActual
Apr 6, 2017
Primary completionActual
Jan 20, 2021
CompletionActual
Feb 17, 2021
Results delay requested
Oct 29, 2021
Results first posted
Apr 8, 2022
Last update
Apr 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03077412
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Mar 13, 2017
Start date
Apr 6, 2017
Primary completion
Jan 20, 2021
Completion
Feb 17, 2021
Results posted
Apr 8, 2022
Last update
Apr 8, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion